Cytomegalovirus reactivation in patients with multiple myeloma administered daratumumab-combination regimens.

Dear Editor, Daratumumab (Dara)-combination regimens have shown promising outcomes for patients with newly diagnosed multiple myeloma (NDMM) or relapsed and refractory multiple myeloma (RRMM). These patients (median age = 61 years; range = 46-75) were treated as follows: Dara/bortezomib/dexamethasone ( I n i = 13), Dara/lenalidomide/dexamethasone ( I n i = 1), and Dara/bortezomib/melphalan/prednisone ( I n i = 1). [Extracted from the article]